Alexion’s Soliris wows in rare disease PhIII trial, opening up a new franchise worth $500M-$700M

Three years after it launched, Alexion $ALXN says that the Phase III study of its cash cow Soliris for rare cases of relapsing neuromyelitis optica spectrum disorder scored a clear and convincing win, setting up some near term applications that one prominent analyst expects could be worth up to $700 million a year in new money.